FDA
-
-
-
-
-
-
-
Aldeyra Therapeutics (ALDX) PT Raised to $7 at Jefferies
-
-
-
-
-
-
-
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
-
-
-
-
-
-
-
Aldeyra Therapeutics (ALDX) Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
-
-
-
-
-
-
-
ALDX SHAREHOLDER ALERT: BFA Law Reminds Aldeyra Therapeutics, Inc. Investors of the Continuing Securities Investigation
-
-
-
-
-
-
-
ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about the Securities Investigation
-
-
-
-
-
-
-
ALDX CLASS REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded to Contact BFA Law about the Pending Securities Investigation
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

